FDA Approves Drug for Aggressive Glioma

Jazz Pharmaceuticals bet $1 billion on the commercial potential of a first-in-class oral imipridone for recurrent H3 K27M-mutant diffuse glioma. Medscape Medical News

Read the full article on medscape.com